Chiesi Group announced that it will spend €430 million to construct a new manufacturing facility on a site that it has acquired in Nerviano, Italy. The site will produce metered dose inhalers with low global warming potential (LGWP) propellants and will have development facilities for sterile biologics and dry powder inhalers. Plans for the 124,000 sq m site include over 3,000 sq m of laboratory space as well as solar energy generation facilities and a 20,000 sq m natural area with trees.
According to Chiesi, the Nerviano site is expected to provide about 300 new jobs for the region by 2029. The company notes that the was previously home to an oncology research center that had several owners between its construction in the 1980s and its closure in 2024.
In December 2019, Chiesi said that it planned to launch an HFA 152a inhaler by the end of 2025. In April 2024, the company announced the initiation of a Phase 3 trial of its HFA 152a version of the Trimbow beclometasone / formoterol / glycopyrronium MDI. Data from that trial are expected later this year.
Chiesi Group CEO Giuseppe Accogli commented, “We chose Nerviano for its strategic location and the potential of the industrial area, which we will transform into a center of excellence for the production of next-generation inhalers. This investment strengthens our presence in Italy and Europe, consolidates our leadership in the sector, and creates new growth opportunities for the local community. It also complements our significant investments in the Parma area, notably our recent Biotech Center launch.”
Read the Chiesi press release
